Related by context. All words. (Click for frequent words.) 71 HDAC Inhibitor 70 Hsp# Inhibitor 70 Protein Kinase C 69 Tyrosine Kinase Inhibitor 69 CYT# potent vascular disrupting 69 CYP#A# CYP#D# 69 IAP inhibitor 69 Kinase Inhibitor 69 liposomal formulation 69 alpha folate receptor 68 Files IND 68 Factor Receptor 68 histone deacetylase HDAC inhibitor 68 Proc Am Soc 68 small molecule tyrosine 68 reversible inhibitor 68 hypoxia inducible factor 68 cyclin dependent kinase inhibitor 68 investigational humanized monoclonal antibody 68 selective inhibitor 67 Novel Oral 67 Xanafide 67 selective antagonist 67 targeted antifolate 67 ERK1 2 67 Signaling Pathway 67 DNA intercalator 67 thymidylate synthase TS 67 Protein Kinase 67 novel histone deacetylase 67 Degarelix 67 vesicular monoamine transporter 67 pan HDAC inhibitor 67 EGFR HER2 67 Bruton tyrosine kinase Btk 67 Aurora Kinase 67 Fc fusion protein 67 protein tyrosine phosphatase 1B 67 histone deacetylase inhibitor 67 Akt activation 67 apoptosis proteins 67 Immunotherapeutic 67 receptor tyrosine kinase inhibitor 67 mda 7 67 Alfacell proprietary ribonuclease 66 Recombinant Human 66 MEK ERK 66 Bosutinib 66 EXECUTIVE SUMMARY II 66 humanized monoclonal 66 potently inhibits 66 Pharmacokinetics PK 66 fosbretabulin 66 Epidermal Growth Factor Receptor 66 Cytochrome P# 66 prostanoid 66 signal transduction inhibitor 66 small molecule inhibitor 66 TO AVOID PREGNANCY WHILE 66 phosphatidylinositol 3 66 induces apoptosis 66 Macrophage 66 selective inhibition 66 accumulate preferentially 66 DNA demethylating agent 66 novel topoisomerase 66 Upregulation 66 HDACi 66 Janus kinase 66 HER1 66 Interferon gamma 66 Hematopoietic 66 cyclin dependent kinases 66 Tumor Necrosis Factor 66 vinca alkaloid 66 PI3K/mTOR 66 vascular disrupting agent 66 Phosphorylation 66 MET VEGFR2 66 Nucleic Acids Res 66 histone deacetylase 66 Deforolimus 66 mediated inhibition 66 Meets Primary Endpoint 66 Sapacitabine 66 serine threonine 66 Omacetaxine 66 ADP receptor antagonist 66 ARRY # 66 bevacizumab Avastin R 66 Locked Nucleic Acid LNA 66 effector function 65 PNP inhibitor 65 3 kinase PI3K 65 vascular disrupting agents 65 RAS MAPK pathway 65 targeting CD# 65 poly ADP ribose polymerase 65 tumor vascular disrupting 65 Aptamer 65 regulated kinase 65 chimeric monoclonal antibody 65 uricase 65 polymerase inhibitor 65 Dalbavancin 65 Prolongs Survival 65 irreversible inhibitor 65 Pralatrexate 65 MEK inhibitor 65 deacetylase 65 Histone Deacetylase 65 ABLYNX 65 Antitumor 65 AAG geldanamycin analog 65 selectively inhibits 65 systemic fungal infections 65 investigational oral inhibitor 65 Systemic Delivery 65 DNA methyltransferase inhibitors 65 novel VDA molecule 65 vapreotide acetate 65 novel emulsion formulation 65 sunitinib Sutent ® 65 orally administered inhibitor 65 Talabostat 65 triciribine phosphate monohydrate 65 topoisomerase II inhibitor 65 Platelet Derived Growth 65 Plaque Psoriasis 65 Antigen Specific 65 downstream effector 65 myelofibrosis polycythemia vera 65 peripherally restricted 65 p# mitogen activated 65 agonistic human 65 Oral Fingolimod 65 dasatinib Sprycel 65 selective kinase inhibitor 65 Chemokine Receptor 65 Liposomal 65 erlotinib Tarceva ® 65 Kinase Inhibitors 65 nucleoside analog 65 dasatinib Sprycel ® 65 Vidofludimus 65 Blinatumomab 65 FOLOTYN ® 65 Transfection 65 CDK inhibitor 65 Presents Preclinical Data 65 PI3 Kinase 65 Bucindolol 65 Granulocyte Colony Stimulating Factor 65 p# inhibitor 65 estrogen receptor antagonist 65 PI3K Akt 65 Tumor necrosis factor 65 Integrin 65 oral prodrug 65 kidney urologic 65 Crit Rev 65 Mg Usa 65 taxane derivative 65 anti CD3 65 cytotoxic conjugate 65 Janus Kinase 65 Gamma secretase 65 NS5A 65 Anti Tumor 65 multi kinase inhibitor 65 Cytotoxic 65 kinase PI3K 64 Anti CD# Antibody 64 CHAMPION PCI 64 Severe Sepsis 64 ERK phosphorylation 64 highly selective inhibitor 64 CD# monoclonal antibody 64 Phase #b/#a clinical 64 ENMD # 64 NS5b 64 Flt3 64 MGd 64 cell adhesion molecule 64 extracellular signal 64 MEK1 64 JAK2 Inhibitor 64 Fas ligand 64 Factor VEGF 64 platinum chemotherapeutic 64 targeted radiotherapeutic 64 intravesical infusion therapy 64 Secretase 64 monocytes macrophages 64 Systemic lupus erythematosus SLE 64 c Raf kinase 64 Prodrug 64 selectively inhibited 64 Lymphocytic 64 Orally administered 64 Cardiotoxicity 64 Oncogenic 64 adipogenic 64 fast skeletal troponin 64 Enzastaurin 64 Orthop Surg 64 Polymerase Inhibitor 64 mitotic kinesin 64 delta isoform 64 leukotriene pathway 64 potent cytotoxic 64 Recurrent Glioblastoma 64 Aplidin R 64 Fibroblast 64 peptibody 64 PI3 kinase 64 Epstein Barr Virus EBV 64 AKT inhibitor 64 Monoclonal Antibody 64 HuLuc# 64 PDE4 inhibitor 64 Preclinical Data 64 mTOR kinase 64 Pertuzumab 64 TKB# 64 platform HDL Mimetic 64 Cytotoxic T 64 Randomized Double blind 64 selective modulator 64 non nucleoside inhibitor 64 Preclinical Study 64 JAK1 64 Temsirolimus 64 dependent kinase inhibitor 64 Eg5 64 Elvitegravir 64 5 HT2A inverse 64 Vascular Disrupting Agent 64 sodium glucose cotransporter 64 Psychiatry Clin Neurosci 64 mediated apoptosis 64 IMiDs R 64 matrix metalloproteases 64 NPC 1C 64 Granted Orphan Drug 64 ribonucleotide reductase 64 Completes Patient Enrollment 64 colony stimulating factor 64 Lenalidomide 64 Initiates Phase II 64 Voreloxin 64 RNAi Therapeutic 64 Inhibits 64 Vascular Endothelial Growth 64 histone deacetylase HDAC 64 pathophysiological effects 64 Gleevec resistant 64 PDE4 64 RAS RAF MEK 64 MET RET 64 methionine aminopeptidase 64 anionic backbone 64 Vaccine Adjuvant 64 Progenitor Cells 64 Receives Orphan Drug Designation 64 oral proteasome inhibitor 64 selectively binds 64 Factor VIIa 64 Personalized Immunotherapy 64 2 inhibitor CYT# 64 DG# compounds targeting 64 PI3K/Akt 64 Initiates Clinical 64 Prospective Randomized 64 HuMax 64 PARI Pharma GmbH 64 reversible inhibitors 64 Vitro Activity 63 tumors GIST 63 c MET 63 Phase IIb Clinical Trial 63 somatostatin analog 63 refractory chronic lymphocytic 63 ErbB1 63 osteogenic 63 small molecule glucokinase 63 Glufosfamide 63 RAF kinase 63 mTOR inhibitors 63 antisense oligonucleotide 63 M2 subunit 63 5 HT2A serotonin 63 potent suppressor 63 demethylating agent 63 PATENT FOR 63 cyclin dependent kinase 63 Maribavir 63 Epithelial 63 cortisol synthesis 63 ® C1 esterase 63 PEGylated anti 63 M1 muscarinic 63 complement inhibitor eculizumab 63 mertansine 63 Dasatinib 63 Combination REOLYSIN R 63 #:#-# [020] 63 5 HT6 receptor 63 immunoregulatory 63 FGFR 63 Proteasome 63 Transcription Factor 63 potent antiproliferative 63 rxRNA 63 R roscovitine CDK cyclin 63 vidofludimus 63 PI3K inhibitor 63 ERK pathway 63 AEG# 63 Vidaza ® 63 Decitabine 63 MKC# MKC# PP 63 ALN TTR 63 metastatic malignant 63 IKK epsilon 63 Vidaza R 63 Cloretazine 63 P#X# 63 mitogen activated protein kinase 63 receptor monoclonal antibody 63 generation purine nucleoside 63 microRNA profiling 63 potently inhibited 63 Transdermal Delivery 63 amikacin 63 JAK2 enzyme 63 Phase III Clinical Trial 63 Tumor Response 63 oral Factor Xa 63 abstr 63 familial amyloidotic polyneuropathy FAP 63 Modulates 63 siRNA therapeutic 63 Diabetic Neuropathy 63 HCV protease 63 Initiates Enrollment 63 humanized anti 63 Tie2 63 mTOR mammalian target 63 Medullary Thyroid Cancer 63 immunomodulatory therapy 63 brand ciclesonide HFA 63 bevacizumab Avastin ® 63 PTP 1B 63 Pivotal Phase III 63 ALN HPN 63 cathepsin K inhibitor 63 DNA methyltransferases 63 OvaRex R 63 mineralocorticoid receptor 63 DUROS 63 Ecallantide 63 triggers apoptosis 63 IL #E 63 PROSTASCINT R 63 Polymorphisms 63 Advanced Renal Cell 63 HuCAL GOLD R 63 vinorelbine tartrate 63 sphingosine 1 63 virus AAV 63 MAGE A3 ASCI 63 serine threonine kinase 63 5 HT4 63 Oncolytic 63 bispecific 63 eIF2 63 Phase 1b Clinical Trial 63 N methyl 63 Monoclonal 63 Prodarsan R 63 Submits IND 63 orally bioavailable 63 Romidepsin 63 Mol Cell 63 pralatrexate injection folate analogue 63 Anticalin ® 63 potently inhibit 63 ERK signaling 63 EGIR 63 CD4 monoclonal antibody 63 TNF Tumor Necrosis Factor 63 aberrantly activated 63 MTP inhibitor 63 proteasome inhibitor 63 mu opioid receptor antagonist 63 Phase 1a clinical 63 dSLIM 63 huN# DM1 63 Small Molecule 63 cetuximab Erbitux R 63 Sevelamer 63 glycopeptide 63 Demonstrates Significant 63 NS5B polymerase 63 inhibit oxidative stress 62 specific protein tyrosine 62 ON #.Na 62 small molecule activators 62 Receptor Agonist 62 Apoptotic 62 pDC 62 protein kinase inhibitor 62 Receptor Antagonist 62 MT# MEDI 62 Anticancer Agent 62 Stromal 62 Anticalin R 62 J Am Acad 62 Locked Nucleic Acid 62 multikinase inhibitor 62 Submits NDA 62 intravesical instillation 62 chemokine receptor 62 Cannabinoid 62 Tyrosine Kinase 62 aurora kinase 62 Aurora kinase 62 5 HT3 antagonist 62 Selective Inhibitor 62 Cathepsin B 62 NS#/#A protease 62 Catenin 62 TLR9 agonist 62 novel peptide 62 developing Bicifadine serotonin 62 Dehydrogenase 62 Dendritic Cells 62 PEGylated Fab fragment 62 treat chronic sinusitis 62 antibody MAb 62 attach auristatin 62 HCV polymerase 62 tyrosine kinase inhibitor 62 ara C 62 Receptor Signaling 62 Novel Inhibitor 62 E3 ligase 62 TGF Beta 62 p# subunit 62 small molecule Hedgehog 62 Ad5FGF 4 62 HCV NS3 protease 62 XL# anticancer compounds 62 nicotinic acetylcholine receptor 62 Phase 2a Clinical Trial 62 NFkB 62 Phase 2b Clinical Trial 62 beta 1a 62 depsipeptide 62 tyrosine kinase receptor 62 CCR9 antagonist 62 serine protease 62 lexidronam injection 62 IFN g 62 AnaSpec Introduces 62 antiapoptotic 62 glycoprotein GP IIb IIIa 62 tumor xenograft models 62 HepDirect prodrug 62 MKC# MT 62 CYP#A# isoenzyme 62 Myeloid 62 Commences Phase 62 constitutively active 62 chronic eosinophilic leukemia 62 Phase Ib II 62 Fingolimod 62 Complicated Skin 62 cyclin dependent kinase CDK 62 biomodulator 62 delipidation 62 Diffuse Large B 62 oral kinase inhibitor 62 protein tyrosine phosphatase 62 Nat Clin Pract 62 alkylating agent 62 factor VIIa 62 inhibitor PPI 62 acetonide FA 62 product platforms AZX# 62 agent VDA 62 VEGF receptor 62 Cutaneous T 62 tumorigenicity 62 G Protein Coupled 62 pan histone deacetylase 62 optical biosensors 62 plasmid encoding 62 folate analogue metabolic 62 TNF Alpha 62 Transmembrane 62 Inhibitor 62 p# alpha [001] 62 phosphorylates 62 secretory phospholipase A2 62 CD3 monoclonal antibody 62 immunostimulatory 62 Polymorphism 62 Antithrombin 62 small molecule thrombopoietin 62 histone acetyltransferase 62 intratumoral injection 62 IMiDs ® compound 62 pro angiogenic 62 CYC# 62 Tezampanel 62 non nucleoside HCV 62 mTOR inhibitor 62 anti angiogenic agent 62 J Biol Chem 62 Fibroblast Growth Factor Receptor 62 HER pathway 62 TELINTRA 62 Tumor Angiogenesis 62 MDRNA proprietary 62 TRAIL induced apoptosis 62 Telik logo TELINTRA 62 ATRA IV 62 4 PDE4 enzyme 62 WEB OF SCIENCE 62 acetylcholinesterase AChE 62 PSMA ADC 62 Files Investigational 62 acadesine 62 candidates Azedra TM 62 mediated phosphorylation 62 LHRH receptor positive 62 Anthrax Toxin 62 LRP5 62 phosphoprotein 62 oral Janus kinase 62 kinesin spindle protein 62 PDGF receptor 62 potent topoisomerase II 62 recombinant adeno associated 62 Symadex 62 bFGF 62 ThermoDox ® clinical 62 specific lectin receptors 62 Protein Expression 62 proprietary polysaccharide 62 JAK#/JAK# 62 somatostatin analogue 62 peptidic compound 62 sorafenib tablets 62 Adjuvant Treatment 62 PDGFR B 62 NeoLipid R 62 Corgentin 62 R lenalidomide 62 SPRYCEL ® 62 androgen receptor AR 62 samarium Sm 62 promoter methylation 62 prostaglandin synthesis 62 Intravenous Human 62 SIRT2 62 metastatic neuroendocrine tumors 62 Pharmacokinetic Study 62 phosphoinositide 3 62 cMET 62 Phase IIb Trial 62 CINtec R 62 Poly ICLC 62 Tesetaxel 62 EZN 62 cytotoxic effects 62 potent inducer 62 NF kappaB activation 62 Achieves Primary Endpoint 62 Alkaline Phosphatase 62 triggers apoptosis programmed 62 Hormone Refractory Prostate Cancer 62 Bortezomib 62 Smooth Muscle 62 Angiogenic 62 gefitinib Iressa 62 Interferon alfa 62 Inhibitory 62 cMet 62 activin receptor type 62 See CLINICAL PHARMACOLOGY 62 IN PATIENTS WITH 61 HIF 1α 61 Humanized Anti 61 Monoclonal antibody 61 immune modulator 61 Mimetics 61 proliferator activated receptor 61 Epratuzumab 61 Interferon beta 61 antisense inhibitor 61 TRAIL R2 61 cyclin dependent kinases CDKs 61 DiLA2 61 diagnostic molecular imaging 61 Pafuramidine 61 patented Bioral 61 5 HT6 61 delta gamma agonist 61 Plasmid DNA 61 cytokine signaling 61 telomerase reverse transcriptase 61 Nephrol 61 Pruvel TM 61 liposome encapsulated 61 Randomized Phase 61 Study Evaluating 61 Nucleoside 61 immunomodulator 61 Aflibercept 61 PDE1 61 J Allergy Clin 61 R roscovitine 61 c myb 61 immune modulatory 61 introduced NEUGENE 61 peripherally acting 61 receptor tyrosine kinase 61 Xyfid TM 61 EGF receptor 61 Announces Poster Presentations 61 TIMP 1 61 PI3K/Akt pathway inhibitor 61 induce apoptosis 61 Completes Enrollment 61 cytotoxic T lymphocyte 61 Nilotinib 61 Anti angiogenic 61 OrbusNeich patented endothelial progenitor 61 SUTENT ® 61 IGF1R 61 Histone 61 Disease Progression 61 HIF PH 61 Denufosol 61 Nedd4 61 paclitaxel Taxol 61 metalloprotease 61 Tumor Suppressor 61 D aspartate NMDA receptor 61 Squalamine 61 alpha antagonist 61 HuCAL R 61 Adenoviral 61 proapoptotic 61 Int J Obes Relat 61 hyaluronidase enzyme 61 TAFA# 61 Therapeutic Competitors Companies 61 Replacement Therapy 61 Methylnaltrexone 61 PDGF B 61 epigenetic therapies 61 siRNA binds 61 Carfilzomib 61 potent inhibitor 61 Abstract Number 61 MEK inhibitors 61 Adult Stem Cell Therapy 61 antiproliferative activity 61 Preclinical Models 61 Initiates Clinical Trial 61 OXi# 61 Successfully Completes Phase 61 drug conjugate 61 Rigel R# 61 β2 61 Antisense Oligonucleotides 61 Subunit 61 histone deacetylase HDAC inhibitors 61 TRANSDUR ™ 61 Phase III Pivotal 61 Child Adolesc Psychiatry 61 protein tyrosine kinase 61 Pathway Inhibitor 61 Receives CE Marking 61 oral JAK1 61 VNP#M 61 HGS ETR1 mapatumumab 61 Hepatocytes 61 mitogen activated protein kinases 61 interleukin IL -# 61 P2Y 61 S#P# 61 humanised antibody 61 microtubule inhibitor 61 Cloretazine VNP#M 61 dihydrofolate reductase 61 Antitumor Activity 61 Receptor Antagonists 61 LPA1 receptor 61 mitogen activated ERK kinase 61 cytoprotective 61 J Am Soc 61 KSP inhibitor 61 T#I [002] 61 abnormal p# 61 PROTEGE 61 Antiviral Therapy 61 paclitaxel poliglumex 61 EGFR TK 61 certain protein tyrosine 61 r hGH 61 Veronate R 61 Randomized Phase II 61 dopamine D2 61 TTR gene 61 THAT ARE DIFFICULT TO 61 Acute Ischemic Stroke 61 Microtubule 61 Anti Tumor Activity 61 selective immunoproteasome inhibitor 61 Kahalalide F 61 Pivotal Trial 61 FGFR3 61 constitutively activated 61 Morpholino 61 E#F# 61 downregulates 61 Therapeutic Vaccine 61 Yondelis ® 61 Secondary Hyperparathyroidism 61 corticosteroid dexamethasone 61 Metastatic Melanoma 61 monoclonal antibody mAb 61 RON Notch 61 mGluR2 NAM 61 isoform selective 61 V#F mutation 61 humanized monoclonal antibodies 61 KL4 Surfactant 61 drug zotarolimus 61 Vandetanib 61 rusalatide acetate 61 Nampt 61 including cyclosporine methotrexate 61 XL# XL# 61 sarcoma melanoma 61 GMX# 61 Peroxisome Proliferator Activated Receptor 61 HIF 1a 61 upregulates 61 anti miRs antisense oligonucleotide 61 COX2 61 GRNOPC1 contains 61 VEGFR2 inhibitor 61 mitogenic 61 Wnt beta catenin 61 Ceflatonin R 61 kinase inhibition 61 Extracellular Matrix 61 immunomodulation 61 Cdc7 61 Polymerase 61 CCR5 antagonist 61 SensoLyte ® 61 selective agonist 61 FASEB J. 61 reverse transcriptase inhibitor 61 selective adhesion molecule 61 Intravascular 61 beta1 61 Annexin V 61 Curaxin 61 kinase inhibitor 61 JAK2 inhibitor 61 inflammatory PDE 61 TLK# 61 eIF4E 61 Pharmaceutica Ltd. 61 Cyclooxygenase 2 61 Phase 2b Trial 61 HSP# inhibitor 61 Initiate Phase 61 BCR ABL1 61 chemokine SDF 1 61 Pemetrexed 61 Initiates Phase 61 phosphoinositide 61 Reports Preclinical Data 61 J Am Coll 61 somatostatin 61 CCR2 61 Treatment Naïve 61 T#M 61 A3 adenosine receptor 61 Vicriviroc 61 Presents Preclinical 61 kinesin spindle protein KSP 61 hypereosinophilic syndrome 61 selective adenosine 61 Glucagon Like Peptide 61 protein kinase inhibitors 61 Anavex #-# 61 Shows Promise Against 61 osteoblast 61 Simulect 61 THR beta agonist 61 BAL# [001] 61 oral Hsp# inhibitor 61 Curaxins 61 HGS# 61 underlying vasculopathy 61 adenosine A2A 61 androgen independent 61 5 hydroxytryptamine 61 Progenitor Cell 61 partial agonist 61 LymphoStat B belimumab 61 BiTE R 61 proteasome inhibitors 61 novel orally administered 61 BXT # 61 DAVANAT 61 catalytic antioxidant compounds 61 C5aR 61 metaglidasen 61 DEV DA TOMAR NEXT 61 Clinical Trial Results 61 Ridaforolimus 61 AQ4N 61 Immunomodulatory 61 Dystrophin 61 SPL# Gel vaginal microbicide 61 cytostatic 61 rALLy clinical trial 61 Myelofibrosis 61 Phase 2b Study 61 Protease Inhibitor 61 receptor kinase 61 CYP#A# substrate 61 Inhalation Solution 61 FasL 61 essential thrombocythemia ET 61 metabolic inhibitor 61 Endothelial 61 oral dihydropyrimidine dehydrogenase DPD 61 Adrenergic 61 p# MAPK 61 cutaneous T 61 Cell Proliferation 61 XYOTAX TM 61 stable nucleic acid 61 5 HT2A receptor 61 Antiangiogenic 61 BiTE Antibody 61 Pentad TM 61 Aliskiren 61 HCV NS5B polymerase 61 GPC3 61 HER2 overexpression 61 reslizumab 61 MorphoSys proprietary 61 biliary tract cancer 60 Cloretazine ® 60 imatinib Gleevec ® 60 PRT# 60 CCR5 co 60 alpha TNFa 60 aspartyl 60 Panzem R 60 Fondaparinux 60 Bayer HealthCare Onyx Pharmaceuticals 60 Ziprasidone 60 Tumor Targeting 60 Endocrinol Metab 60 nilotinib Tasigna ® 60 By JAMAAL ABDUL 60 IMiDs ® 60 Vinorelbine 60 Epitope 60 FLT3 60 Glucocorticoid 60 Potent Inhibitor 60 prescribed proton pump 60 cytolytic 60 c MYC 60 #beta HSD1 60 BCL2 60 Myelodysplastic Syndrome MDS 60 CBLC# 60 specific CCR9 antagonist 60 ErbB3 HER3 60 SCH # 60 interferon IFN 60 JAK inhibitor 60 Aeolus Pharmaceuticals Announces 60 vitro assay 60 novel immunomodulatory 60 vWF 60 ACC2 60 ADAMTS# 60 Vaprisol 60 MKC# 60 Phase Ib Clinical Trial 60 Survivin 60 inhaled formulation 60 regarding Aethlon Medical 60 humanized monoclonal antibody 60 vivo fluorescence imaging 60 Eur J Endocrinol 60 Cytotoxicity 60 Antiviral Activity 60 hypoxia activated prodrug 60 including thyroiditis RA 60 SGLT 2 60 Cell Mol Physiol 60 induced apoptosis 60 CEQ# 60 orally dosed 60 TRO# 60 Myolimus 60 oral ghrelin agonist 60 phosphatidylserine PS targeting 60 Randomized Double Blind Placebo 60 phosphate S1P 60 proteomics bioinformatics 60 antiangiogenic agent 60 intercellular adhesion molecule 60 selectively inhibit 60 Presents Positive Preclinical 60 isoenzyme 60 Epidermal growth 60 highly selective endothelin 60 ABL1 60 SGLT 60 Induces Apoptosis 60 ErbB 60 HIF 1alpha 60 CTAP# Capsules 60 selective A2A adenosine receptor 60 murine model 60 Panzem R NCD 60 AFREZZA TM 60 Raf kinase 60 Wafer polifeprosan 60 AAV vector carrying 60 Androgen Receptor 60 Clusterin 60 cAMP signaling 60 cyclooxygenase 2 60 Multiple Myeloma MM 60 Epothilone 60 HER2 ErbB2 60 Perifosine KRX 60 Fleximer 60 Phase IIa Clinical Trial 60 PKC isoforms 60 peptide receptor 60 Panzem NCD 60 Dendritic Cell 60 benzimidazole 60 Clinical Outcome 60 plasma kallikrein inhibitor 60 MicroRNA 60 factor HGF 60 acute peripheral arterial 60 Hedgehog Pathway Inhibitor 60 ALK inhibitor 60 Darinaparsin 60 Varespladib 60 Oral NKTR 60 DNA Methylation 60 recombinant interferon 60 NASH Huntington 60 Tß4 60 Anidulafungin 60 IL #p# 60 VEGFR2 60 Ambrisentan 60 Nucleic Acids 60 orally bioavailable mimics 60 world safest multivalent 60 IMC A# 60 Phase 2a Trial 60 dual PPAR peroxisome 60 THERAPEUTICS 60 NABTT 60 antimitotic 60 cytidine nucleoside analog 60 subcutaneous immunoglobulin 60 recurrent metastatic ovarian cancer 60 retinoic acid receptor 60 adrenoceptor 60 Vorinostat 60 Hycamtin ® 60 II Clinical Trial